Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2025-04-11 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
2024年年度财务报告
Annual Report Classification · 100% confidence The document is titled '云南沃森生物技术股份有限公司2024 年度财务报告' which translates to 'Yunnan Watson Biotechnology Co., Ltd. 2024 Annual Financial Report'. It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and notes. It also includes a comprehensive audit report with audit opinions, audit basis, key audit matters, and responsibilities of management and auditors. The presence of a full audit report and detailed financial data for the fiscal year 2024 indicates this is a full annual report. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Annual Report (10-K). FY 2024
2025-04-11 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 26th meeting of the 5th Board of Directors of Yunnan Watson Biotechnology Co., Ltd. It includes approvals of the 2024 annual report, audited financial report, financial budget, internal control evaluation report, sustainable development report, profit distribution plan, and other corporate governance matters. The document also mentions that these reports are available on the designated disclosure website, indicating this document itself is not the full annual report but a board meeting resolution announcement. The content focuses on board decisions and approvals rather than presenting the full financial statements or detailed management discussion. Therefore, this document fits best under the category of Board/Management Information (MANG), as it announces board meeting resolutions and management decisions.
2025-04-11 Chinese
董事会对独董独立性评估的专项意见
Governance Information Classification · 95% confidence The document is a special opinion from the board regarding the independence of the company's independent directors, referencing regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange guidelines. It is a governance-related statement about board members' independence and compliance with governance rules. The document is short (486 characters) and does not contain financial data, audit results, or voting results. It is not an announcement of a meeting or voting results, nor a financial report. This fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-04-11 Chinese
2024年度独立董事述职报告（赵健梅）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Report" for the year 2024 by an independent director of the company. It details the director's activities, attendance at board meetings, opinions on major company matters, committee work, communication with auditors, and protection of investor rights. It does not contain financial statements or comprehensive financial data itself but rather a narrative report on the director's duties and oversight during the year. This type of document is typically classified under Board/Management Information (MANG) as it relates to governance and management oversight rather than a full annual report or audit report. The document length is about 4750 characters, which is sufficient for a detailed report but it is not a financial report per se. Therefore, the best fit is MANG.
2025-04-11 Chinese
2024年度独立董事述职报告（孙钢宏）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Report" for the year 2024 from Yunnan Watson Biotechnology Co., Ltd. It details the independent director's activities, attendance at board and shareholder meetings, opinions on major company matters, committee work, supervision of financial reports, appointment of auditors and senior management, and protection of investor rights. The content is a detailed narrative of management and board oversight rather than a financial statement or audit report. It does not contain financial statements or earnings data but focuses on governance and management oversight. This aligns with the category of Board/Management Information (MANG), which covers announcements of changes and reports related to the company's board and senior management activities. The document is about the independent director's duties and opinions, fitting MANG rather than other categories like Annual Report or Audit Report. The document length is about 4985 characters, sufficient for a detailed report but not a full financial report. Therefore, the classification is MANG with high confidence.
2025-04-11 Chinese
关于2024年第四季度计提资产减值准备及年度核销资产的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding the 2024 fourth quarter asset impairment provisions and annual asset write-offs. It details the amounts of impairment provisions, the accounting standards applied, and the impact on profits and equity. It includes board and audit committee opinions approving these accounting decisions. The document is a formal disclosure of accounting estimates and adjustments rather than a full financial report or earnings release. It is not a full annual or interim report, nor a call transcript or presentation. It is a regulatory announcement about asset impairment and write-offs, which fits best under Regulatory Filings (RNS) as it does not constitute a full audit report or annual report but is a compliance disclosure related to accounting estimates and asset valuation adjustments.
2025-04-11 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.